Contrasting Biohaven Pharmaceutical Holding Co (BHVN) and ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals (NASDAQ: ANIP) and Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitabiliy, analyst recommendations and valuation.
Valuation & Earnings
This table compares ANI Pharmaceuticals and Biohaven Pharmaceutical Holding Co’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|ANI Pharmaceuticals||$144.70 million||3.83||$58.86 million||$0.33||144.49|
|Biohaven Pharmaceutical Holding Co||N/A||N/A||N/A||N/A||N/A|
ANI Pharmaceuticals has higher revenue and earnings than Biohaven Pharmaceutical Holding Co.
This is a summary of current ratings and price targets for ANI Pharmaceuticals and Biohaven Pharmaceutical Holding Co, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Biohaven Pharmaceutical Holding Co||0||0||5||0||3.00|
ANI Pharmaceuticals presently has a consensus target price of $68.00, suggesting a potential upside of 42.62%. Biohaven Pharmaceutical Holding Co has a consensus target price of $31.75, suggesting a potential upside of 32.24%. Given ANI Pharmaceuticals’ higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Biohaven Pharmaceutical Holding Co.
This table compares ANI Pharmaceuticals and Biohaven Pharmaceutical Holding Co’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Biohaven Pharmaceutical Holding Co||N/A||N/A||-172.50%|
Insider and Institutional Ownership
55.5% of ANI Pharmaceuticals shares are held by institutional investors. 31.6% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
ANI Pharmaceuticals beats Biohaven Pharmaceutical Holding Co on 7 of the 9 factors compared between the two stocks.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Biohaven Pharmaceutical Holding Co Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.